An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Stopped early · Phase 1/Phase 2
Conditions studied: Solid Tumors and Hematologic Malignancy
In brief
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
Key facts
- Study ID
- NCT02431260
- Run by
- Incyte Corporation
- People needed
- 69
- Starts
- 2015-04-14
- Expected to finish
- 2018-01-31
- Last updated by the study team
- 2019-06-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- University of California, San Francisco, Medical Center at Mount Zion — San Francisco, California, United States
- Sarah Cannon Research Institute Research Center — Denver, Colorado, United States
- Northwestern Memorial Hospital — Chicago, Illinois, United States
- The University of Chicago Medical Center — Chicago, Illinois, United States
- Horizon Oncology Center — Lafayette, Indiana, United States
- John Hopkins — Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Washington University School of Medicine in St. Louis — St Louis, Missouri, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Seattle Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.